Objective  To explore the clinical efficacy of omacycline (OMC) in the treatment of diabetes mellitus complicated with community-acquired bacterial pneumonia (CABP).

Methods  Clinical data of T2DM patients with CABP admitted to The First Hospital of Jiaxing from August 2022 to July 2023 were divided into OMC group and non-OMC (NOMC) group according to wheter they received OMC treatment or not. The absorption of pulmonary lesions after treatment, changes in inflammatory indicators [white blood cell count (WBC), C-reactive protein (C-reactive protein, CRP), and anterior calcitonin (procalcitonin, PCT)], comprehensive index [hospitalization days, total hospitalization costs, blood glucose standard within 3 d and glucocorticoid use] and the occurrence of adverse reactions were analyzed and compared.

Results  A total of 100 diabetes mellitus patients with CABP were included in this study, including 36 cases in OMC group and 64 cases in NOMC group. The absorption of pulmonary inflammation in the OMC group was significantly higher than that in the NOMC group (P<0.05). Before treatment, there was no statistical difference in WBC, CRP and PCT between the two groups (P>0.05). After treatment, WBC, CRP, and PCT in both groups were significantly lower than those before treatment (P<0.05). Furthermore, WBC, CRP, PCT levels, hospital stay, total hospitalization costs and glucocorticoid use rate were significantly lower in the OMC group than in the NOMC group (P<0.05). The blood glucose compliance rate within 3 d in the OMC group was significantly higher than that in the NOMC group (P<0.05). None of the patients had serious complications during the treatment period.

Conclusion  OMC treatment of T2DM complicated with CABP is helpful for early disease control and rehabilitation, and reduces the treatment burden.

1.Sun YX, Li H, Pei ZC, et al. Incidence of community-acquired pneumonia in urban China: a national population-based study[J]. Vaccine, 2020, 38(52): 8362-8370. DOI: 10.1016/j.vaccine.2020.11.004.

2.陈嘉琦, 叶国辉, 肖婉媚, 等. 莫西沙星与左氧氟沙星序贯治疗老年社区获得性肺炎效果比较[J]. 临床合理用药, 2023, 16(5): 80-83. [Chen JQ, Ye GH, Xiao WM, et al. Comparison of sequential treatment effects of moxifloxacin and levofloxacin in elderly community-acquired pneumonia[J]. Chinese Journal of Clinical Rational Drug Use, 2023, 16(5): 80-83.] DOI: 10.15887/j.cnki.13-1389/r.2023.05.025.

3.刘文, 向世强, 龚雅琪, 等. 糖尿病合并尿路感染患者酮症酸中毒的影响因素分析[J]. 医学新知, 2024, 34(3): 276-281. [Liu W, Xiang SQ, Gong YQ, et al. Analysis of influencing factors of ketoacidosis in diabetes patients with urinary tract infection[J]. Yixue Xinzhi Zazhi, 2024, 34(3): 276-281.] DOI: 10.12173/j. issn.1004-5511.202312022.

4.中华医学会呼吸病学分会感染学组. 糖尿病合并肺炎诊治路径中国专家共识[J]. 中华内分泌代谢杂志, 2020, 36(8): 635-642. DOI: 10.3760/cma.j.cn311282-20200508-00335.

5.陈明毅, 唐可京, 陈杰. 奥马环素在特殊人群、特殊病理状态患者中应用研究进展[J]. 中国新药杂志, 2023, 32(22): 2300-2305. [Chen MY, Tang KJ, Chen J. Progress in research on application of omadacycline in special population and patients with special pathological status[J]. Chinese Journal of New Drugs, 2023, 32(22): 2300-2305.] DOI: 10.3969/j.issn.1003-3734.2023.22.012.

6.Stets R, Popescu M, Gonong JR, et al. Omadacycline for Community-Acquired Bacterial Pneumonia[J]. N Engl J Med, 2019, 380(6): 517-527. DOI: 10.1056/NEJMoa1800201.

7.Torres A, Garrity-Ryan L, Kirsch C, et al. Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia[J]. Int J Infect Dis, 2021, 104: 501-509. DOI: 10.1016/j.ijid.2021.01.032.

8.史海燕, 胡英, 黄建荣, 等. 奥马环素对比美罗培南联合利奈唑胺治疗肺部感染: 一项真实世界队列研究[J]. 中华临床感染病杂志, 2023, 16(3): 210-214. [Shi HY, Hu Y, Huang JR, et al. Comparison of omadacycline and meropenem plus linezolid in treatment of pulmonary infection: a real-world cohort study[J]. Chinese Journal of Clinical Infectious Diseases, 2023, 16(3): 210-214.] DOI: 10.3760/cma.j.issn.1674-2397.2023.03.008.

9.Sakoulas G. Linezolid versus omadacycline in diabetic soft tissue infections: a signal of different adjunctive immunological properties?[J]. J Antimicrob Chemother, 2022, 77(6): 1503-1505. DOI: 10.1093/jac/dkac030.

10.刘又宁. 社区获得性细菌性肺炎诊断和治疗指南[J]. 中华结核和呼吸志, 2006, 29(10): 651-655. [Liu YN. Guidelines for the diagnosis and treatment of community-acquired bacterial pneumonia[J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2006, 29(10): 651-655.] DOI: 10.3760/j:issn:1001-0939.2006.10.002.

11.中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J].中华内分泌代谢杂志, 2021, 37(4) : 311-398. DOI: 10.3760/cma.j.cn311282-20210304-00142.

12.杨春霞, 李敏, 刘琰. 补肺消炎方治疗糖尿病合并社区获得性肺炎疗效及对血清炎性因子的影响[J]. 中华中医药杂志, 2019, 34(1): 427-429. [Yang CX, Li M, Liu Y. The therapeutic effect of Bufei Xiaoyan Recipe on diabetes complicated with community acquired pneumonia and its influence on serum inflammatory factors[J]. Chinese Journal of Traditional Chinese Medicine, 2019, 34(1): 427-429.] DOI: CNKI:SUN:BXYY.0.2019-01-120.

13.江真明. 早期血糖水平对老年社区获得性肺炎患者预后影响[J]. 现代预防医学, 2013, 40(11): 2170-2172. [Jiang ZM. Effect of early blood glucose on the of prognosis of community acquired pneumonia of elderly patients[J]. Modern Prevention Medicine, 2013, 40(11): 2170-2172.] DOI: CNKI:SUN:XDYF.0.2013-11-063.

14.中华医学会呼吸病学分会肺部感染学组. 成人社区获得性肺炎基层诊疗指南(2018年)[J]. 中华全科医师杂志, 2019, 18(2): 117-126. DOI: 10.3760/cma.j.issn.1671- 7368.2019.02.005.

15.Pfaller MA, Huband MD, Shortridge D, et al. Surveillance of omadacycline activity tested against clinical isolates from the USA: report from the SENTRY antimicrobial surveillance program, 2019[J]. J Glob Antimicrob Resist, 2021, 27: 337-351. DOI: 10.1016/j.jgar.2021.09.011.

16.Rodvold KA, Burgos RM, Tan X, et al. Omadacycline: a review of the clinical pharmacokinetics and pharmacodynamics[J]. Clin Pharmacokinet, 2020, 59(4): 409-425. DOI: 10.1007/s40262-019-00843-4.

17.Flarakos J, Du Y, Gu H, et al. Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline[J]. Xenobiotica, 2017, 47(8): 682-696. DOI: 10.1080/00498254.2016.1213465.